In patients with osteoporosis, which of the following can indicate a response to bisphosphonate therapy?

In patients undergoing bisphosphonate therapy for osteoporosis, a decrease in N-telopeptide levels is a significant indicator of treatment response. N-telopeptide is a byproduct of collagen breakdown in bone and serves as a marker for bone resorption. Bisphosphonates work by inhibiting osteoclast activity, thereby reducing the rate of bone degradation. When the therapy is effective, the levels of N-telopeptide decrease, reflecting lower bone resorption rates and indicating improved bone health.

Monitoring N-telopeptide levels helps clinicians assess the effectiveness of the treatment. A consistent reduction in these levels suggests that bisphosphonates are working to stabilize or increase bone density, thereby helping to prevent fractures related to osteoporosis.